European Medicines Agency recommends extending use of Nexavar to include treatment of differentiated thyroid cancer

View source ↗

Summary

EMA recommends extending the use of Nexavar (sorafenib) to treat differentiated thyroid cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Cancer

Drugs mentioned

• Nexavar (Sorafenib)